Koya Medical Receives FDA Clearance for Dayspring Lite, Bringing Much-Needed Movement to People Beginning Compression Therapy to Treat Lymphedema and Venous Disease

Sept. 28, 2021 12:00 UTC

 

Dayspring Lite is the latest addition to Koya’s suite of treatment options for lymphedema and venous disease, a condition impacting 20 million Americans

 

OAKLAND, Calif.--(BUSINESS WIRE)-- Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, received Food and Drug Administration (FDA) 510(k) clearance for its Dayspring® Lite treatment for lymphedema and venous disease. Unlike traditional compression pumps that require patients to be tethered to the wall during use, the Dayspring family of treatments enables people to enjoy movement and mobility during their active compression therapy – movement that is important to both quality of life and clinical outcomes.

Dayspring Lite is a prescription-only treatment for people who need to add basic active compression to their lymphedema regimen. It uses the same innovative Flexframe™ technology and smart, rechargeable, hand-held controller available in the Dayspring flagship product. While Dayspring Lite is non-calibrated and provides less customization options than the flagship treatment, the product is designed to meet the needs of those who require more essential compression therapy to clear lymph fluid.

With Dayspring Lite, patients can select and monitor from the Koya app one of three standard treatment intensities. If the patient’s needs evolve to require calibration and additional customization, Koya Medical can support a seamless transition to the more advanced Dayspring therapy.

“Managing chronic diseases like lymphedema, which often occurs as a result of cancer or cancer treatment, is a journey and we know that needs can evolve throughout that journey,” said Andy Doraiswamy, Ph.D., Founder, President and CEO of Koya Medical. “We’re committed to developing treatment options that support patients as they manage all phases of this chronic condition so they can get back to the active, productive lives they enjoy.”

The Dayspring system includes a low-profile active garment made of soft, breathable mesh using Koya's proprietary Flexframe technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to program custom treatment options. Koya previously received FDA 510(k) clearance for the Dayspring flagship product for both upper and lower extremity lymphedema. Koya Medical is committed to providing patients and caregivers a complete suite of solutions that provide coordinated and comprehensive care of this chronic condition.

About Lymphedema

An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein rich fluid causes painful swelling in the arm, leg and/or other regions of the body.1 For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema is commonly caused by cancer and treatment for cancer due to damage of the lymph system from the tumor itself, radiation treatment or the surgical removal of lymph nodes.

About Koya Medical

Koya Medical is transforming and reimagining lymphatic and venous care through people-centered innovations that meaningfully improve lives, empower self-care, increase transparency, and reduce burden on the healthcare system. The privately held company was founded in 2018 around the development of the company’s first treatment Dayspring, a mobility-enabled active compression system. For company or product inquiry, contact info@koyamedical.com. Learn more at koyamedical.com or follow the company on LinkedIn at www.linkedin.com/company/koyamedical/.

1 Dean, S. M., Valenti, E., Hock, K., Leffler, J., Compston, A., & Abraham, W. T. (2020). The clinical characteristics of lower extremity lymphedema in 440 patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8(5), 851–859. https://doi.org/10.1016/j.jvsv.2019.11.014

Contacts

Jenna Mathis
Health+Commerce
jennamathis@healthandcommerce.com
610.751.3985

 
 

Source: Koya Medical

Back to news